Are we witnessing the emergence of a regulatory pathway for innovative medicines that could operate alongside traditional FDA frameworks? Are we witnessing the emergence of a regulatory pathway for innovative medicines that could operate alongside traditional FDA frameworks? by Kristopher Brown, Heath Ingram, and Susan Lee at Goodwin Read the update August 11, 2026 Morning Brief